<i>In Vitro</i>
            Activities of Omadacycline against Rapidly Growing Mycobacteria

Shoen, Carolyn; Benaroch, David; Sklaney, Mary; Cynamon, Michael H.

doi:10.1128/aac.02522-18

Cited by 60 publications

(41 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Likewise, omadacycline and tigecycline had the same MIC 50 and MIC 90 against 28 drug-resistant clinical isolates (2 g/ml), while the MIC 50 and MIC 90 of eravacycline were 2-fold lower. Interestingly, while the present study was under review, a newly published study reported similar MICs for tigecycline and omadacycline against M. abscessus complex clinical isolates (19).…”

supporting

confidence: 50%

In Vitro Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of Mycobacterium abscessus

Kaushik

Ammerman

Martins

et al. 2019

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Tigecycline is used in multidrug regimens for salvage therapy of Mycobacterium abscessus infections but is often poorly tolerated and has no oral formulation. Here, we report similar in vitro activity of two newly approved tetracycline analogs, omadacycline and eravacycline, against 28 drug-resistant clinical isolates of M. abscessus complex. Since omadacycline and eravacycline appear to be better tolerated than tigecycline and since omadacycline is also formulated for oral dosing, these tetracycline analogs may represent new treatment options for M. abscessus infections.

show abstract

supporting

confidence: 50%

In Vitro Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of Mycobacterium abscessus

Kaushik

Ammerman

Martins

et al. 2019

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…A third published study tested omadacycline, tigecycline, and doxycycline against 24 M abscessus isolates [ 9 ]. The MIC 50 /MIC 90 of omadacycline and doxycycline were 1/2 mcg/mL and >64/>64 mcg/mL, respectively.…”

Section: Discussionmentioning

confidence: 99%

Omadacycline for the Treatment of Mycobacterium abscessus Disease: A Case Series

Pearson

Dionne

Richterman

et al. 2020

Open Forum Infectious Diseases

View full text Add to dashboard Cite

Background Omadacycline is an aminomethylcycline antimicrobial approved by the United States Food and Drug Administration in 2018 for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. It has in vitro activity against nontuberculous mycobacteria, including Mycobacterium abscessus complex, but clinical data for this indication are lacking. Methods Omadacycline use was reviewed at an 804-bed academic medical center. Patients were included if they received omadacycline for culture-proven M. abscessus disease in 2019. Results Four patients received omadacycline for the treatment of culture-positive M. abscessus disease in 2019. Two patients had cutaneous disease, one had pulmonary disease, and one had osteomyelitis and bacteremia. The patients received omadacycline for a median duration of 166 days (range 104-227) along with a combination of other antimicrobial agents. Omadacycline-containing regimens were associated with a clinical cure in three of four patients, with one patient improving on ongoing treatment. Omadacycline’s tolerability was acceptable for patients with M. abscessus disease, with one patient discontinuing therapy in month six due to nausea. Conclusions Omadacycline is a novel oral option for the treatment of Mycobacterium abscessus disease, for which safe and effective options are needed. While this case series is promising, further data are required to determine omadacycline’s definitive role in the treatment of Mycobacterium abscessus disease.

show abstract

“…Omadacycline (PO/IV), Eravacycline (PO/IV) omadacycline [32,33] and eravacycline [34,35] have activity against reference and clinical strains N/A Report of one patient-noted clinical improvement [36] Tedizolid (PO/IV)…”

Section: N/amentioning

confidence: 99%

“…Eravacycline (a fluorocycline) is a new tetracycline analog approved for the parenteral treatment of complicated intraabdominal infections [34]. In vitro studies have shown both omadacycline and eravacycline to have similar antimicrobial activity to tigecycline against both reference and clinical M. abscessus strains [32,33,35]. Specifically as omadacycline is available as an oral formulation [58,59], it may have a role in treating chronic M. abscessus infections in outpatient settings.…”

Section: Novel Antimicrobialsmentioning

confidence: 99%

Alternative and Experimental Therapies of Mycobacterium abscessus Infections

Meir

Barkan

2020

IJMS

View full text Add to dashboard Cite

Mycobacterium abscessus is a non-tuberculous mycobacterium notoriously known for causing severe, chronic infections. Treatment of these infections is challenging due to either intrinsic or acquired resistance of M. abscessus to multiple antibiotics. Despite prolonged poly-antimicrobial therapy, treatment of M. abscessus infections often fails, leading to progressive morbidity and eventual mortality. Great research efforts are invested in finding new therapeutic options for M. abscessus. Clofazimine and rifabutin are known anti-mycobacterial antibiotics, repurposed for use against M. abscessus. Novel antimicrobials active against M. abscessus include delamanid, pretomanid and PIPD1 and the recently approved beta-lactamase inhibitors avibactam, relebactam and vaborbactam. Previously unused antimicrobial combinations, e.g. vancomycin–clarithromycin and dual beta-lactam therapy, have been shown to have synergistic effect against M. abscessus in experimental models, suggesting their possible use in multiple-drug regimens. Finally, engineered phage therapy has been reported to be clinically successful in a severe case of disseminated M. abscessus infection. While many of these experimental therapeutics have shown activity against M. abscessus in vitro, as well as in intracellular and/or animal models, most have little if any evidence of effect in human infections. Clinical studies of M. abscesssus treatments are needed to reliably determine the value of their incorporation in therapeutic regimens.

show abstract

In Vitro Activities of Omadacycline against Rapidly Growing Mycobacteria

Cited by 60 publications

References 4 publications

In Vitro Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of Mycobacterium abscessus

In Vitro Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of Mycobacterium abscessus

Omadacycline for the Treatment of Mycobacterium abscessus Disease: A Case Series

Alternative and Experimental Therapies of Mycobacterium abscessus Infections

Contact Info

Product

Resources

About